PERSPECTA

News from every angle

← Back to headlines

Alnylam Targets 25% CAGR with Innovative Therapies

Alnylam Pharmaceuticals is targeting a 25% compound annual growth rate (CAGR) through its focus on innovative therapies.

26 Mar, 07:27 — 26 Mar, 07:27
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual154d ago

Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies

Read full article →

Related Stories

U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates

43m ago

West Nile Virus Outbreaks Spread Across Greece and North Macedonia

1h ago

Kylie Jenner Reveals Plans for Larger Breast Implants

1h ago

World Health Organization Declares Uganda Ebola Outbreak Over

2h ago